SCOPUS 정보 검색 플랫폼

Oncology

Volumn 61, Issue SUPPL. 2, 2001, Pages 58-66

Retrospective analysis of the safety of Herceptin® immunotherapy in metastatic breast cancer

(1) Cook Bruns, Nancy a

a F HOFFMANN LA ROCHE LTD (Switzerland)

Author keywords

Breast cancer; Cardiac safety; Herceptin ; Infusion related reaction; Retrospective analysis; Safety

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARDIAC GLYCOSIDE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; RECEPTOR SUBTYPE; TRASTUZUMAB;

AGE; BREAST METASTASIS; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; DRUG TOLERANCE; HEART DISEASE; HEART PROTECTION; HUMAN; INCIDENCE; MONOTHERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOVASCULAR AGENTS; CHILLS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG INTERACTIONS; FEMALE; FEVER; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; NEOPLASM METASTASIS; PAIN; PALLIATIVE CARE; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; SAFETY; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0034755872 PISSN: 00302414 EISSN: None Source Type: Journal
DOI: 10.1159/000055403 Document Type: Conference Paper

Times cited : (156)

References (27)

1
- 0033910401
- Adverse events associated with chemotherapy for common cancers
- (2000) Pharmacotherapy , vol.20
- Adams, V.R.¹

2
- 0033093978
- First MAb approved for the treatment of metastatic breast cancer
- (1999) J Am Pharm Assoc , vol.39 , pp. 236-238
- Brenner, T.L.¹ Adams, V.R.²

3
- 0034110517
- Cardiac and pulmonary toxicity in patients undergoing high dose chemotherapy for lymphoma and breast cancer: Prognostic factors
- (2000) Bone Marrow Transplant , vol.25 , pp. 885-894
- Brockstein, B.E.¹ Smiley, C.² Al-Sadir, J.³ Williams, S.F.⁴

4
- 0026610881
- Humanization of the anti-p185HER2 antibody for human cancer therapy
- (1992) Proc Natl Acad Sci USA , vol.89 , pp. 4285-4289
- Carter, P.¹ Presta, L.² Gorman, C.M.³ Ridgway, J.B.⁴ Henner, D.⁵ Wong, W.L.⁶ Rowland, A.M.⁷ Kotts, C.⁸ Carver, M.E.⁹ Shepard, H.M.¹⁰

5
- 0032850677
- Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
- (1999) J Clin Oncol , vol.17 , pp. 2639-2648
- Cobleigh, M.A.¹ Vogel, C.L.² Tripothy, D.³ Robert, N.J.⁴ Scholl, S.⁵ Fehrenbacher, L.⁶ Wolter, J.M.⁷ Paton, V.⁸ Shak, S.⁹ Lieberman, G.¹⁰ Slamon, D.J.¹¹

6
- 0033373381
- Antiestrogens - Tamoxifen, SERMS and beyond
- (1999) Invest New Drugs , vol.17 , pp. 285-311
- Dhingra, K.¹

7
- 0032874107
- Cardiotoxicity in patients receiving Trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artefact?
- (1999) Semin Oncol , vol.26 , pp. 96-101
- Ewer, M.S.¹ Gibbs, H.R.² Swafford, J.³ Benjamin, R.S.⁴

8
- 0034682589
- Trastuzumab in the treatment of metastatic breast cancer: Anti-cancer therapy versus cardiotoxicity
- (2000) Circulation , vol.102 , pp. 272-274
- Feldman, A.M.¹ Lorell, B.H.² Reis, S.E.³

9
- 0034254157
- Monoclonal antibody therapy for solid tumors
- (2000) Cancer Treat Rev , vol.26 , pp. 269-286
- Green, M.C.¹ Murray, J.L.² Hortobagyi, G.N.³

10
- 0032740187
- Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
- (1999) Semin Oncol , vol.26 , pp. 66-73
- Grillo-López, A.J.¹ White, C.A.² Varns, C.³ Shen, D.⁴ Wei, A.⁵ McClure, A.⁶ Ballaire, B.K.⁷

11
- 0025002747
- Comprehensive management of disseminated breast cancer
- (1990) Cancer , vol.66 , pp. 1439-1448
- Henderson, I.C.¹ Garber, J.E.² Breitmeyer, J.B.³ Hayes, D.F.⁴ Harris, J.R.⁵

12
- 0032973059
- Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer
- (1999) Drugs , vol.57 , pp. 133-155
- Hoekman, K.¹ Van der Vijgh, W.J.² Vermorken, J.B.³

13
- 0015849162
- A clinicopathological analysis of Adriamycin cardiotoxicity
- (1973) Cancer , vol.32 , pp. 302-314
- Lefrak, E.¹ Pitha, J.² Rosenheim, S.³ Gottlieb, J.A.⁴

14
- 0031785720
- Use of rituximab, the new FDA-approved antibody
- (1998) Curr Opin Oncol , vol.10 , pp. 548-551
- Leget, G.A.¹ Czuczman, M.S.²

15
- 0032978412
- Perception of chemotherapy side effects cancer versus non-cancer patients
- (1999) Cancer Practice , vol.7 , pp. 59-65
- Lindley, C.¹ McCune, J.S.² Thomason, T.E.³ Lauder, D.⁴ Sauls, A.⁵ Adkins, S.⁶ Sawyer, W.T.⁷

16
- 0031761148
- Newer treatments for non-Hodgkin's lymphoma: Monoclonal antibodies
- (1998) Oncology , vol.12 , pp. 63-76
- Maloney, D.G.¹ Press, O.W.²

17
- 0000153682
- The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
- (2000) Proc Am Soc Clin Oncol , vol.19
- Mass, R.D.¹ Sanders, C.² Charlene, K.³ Johnson, L.⁴ Everett, T.⁵ Anderson, S.⁶

18
- 0000212829
- Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
- (1999) Proc Am Soc Clin Oncol , vol.18
- Norton, L.¹ Slamon, D.² Leyland-Jones, B.³ Wolter, J.⁴ Fleming, T.⁵ Eirmann, W.⁶ Baselga, J.⁷ Mendelsohn, J.⁸ Bajamonde, A.⁹ Ash, M.¹⁰ Shak, S.¹¹

19
- 0031903646
- HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-over-expressing metastatic breast cancer refractory to chemotherapy treatment
- (1998) J Clin Oncol , vol.16 , pp. 2659-2671
- Pegram, M.D.¹ Lipton, A.² Hayes, D.F.³ Weber, B.L.⁴ Baselga, J.M.⁵ Tripathy, D.⁶ Baly, D.⁷ Baughman, S.A.⁸ Twaddell, T.⁹ Glaspy, J.A.¹⁰ Slamon, D.J.¹¹

20
- 0029932612
- Tamoxifen in postmenopausal women a safety perspective
- (1996) Drugs Aging , vol.8 , pp. 329-337
- Robinson, E.¹ Kimmick, G.G.² Musa, H.B.³

21
- 0031759864
- The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
- (1998) Stem Cells , vol.16 , pp. 413-428
- Ross, J.S.¹ Fletcher, J.A.²

22
- 0032563825
- Doxorubicin-induced cardiomyopathy
- (1998) N Engl J Med , vol.339 , pp. 900-905
- Singal, P.K.¹ Iliskovic, N.²

23
- 37049183697
- Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
- (1987) Science , vol.235 , pp. 177-182
- Slamon, D.J.¹ Clark, G.M.² Wong, S.G.³ Levin, W.J.⁴ Ullrich, A.⁵ McGuire, W.L.⁶

24
- 0024337144
- Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer
- (1989) Science , vol.244 , pp. 707-712
- Slamon, D.J.¹ Godolphin, W.² Jones, L.A.³ Holt, J.A.⁴ Wong, S.G.⁵ Keith, D.E.⁶ Levin, W.J.⁷ Stuart, S.G.⁸ Udove, J.⁹ Ullrich, A.¹⁰ Press, M.F.¹¹

25
- 0035869407
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
- (2001) N Engl J Med , vol.344 , pp. 783-792
- Slamon, D.¹ Leyland-Jones, B.² Shak, S.³ Paton, V.⁴ Bajamonde, A.⁵ Fleming, T.⁶ Eiermann, W.⁷ Wolter, J.⁸ Baselga, J.⁹ Norton, L.¹⁰

26
- 0001793693
- First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
- (2000) Proc Am Soc Clin Oncol , vol.19
- Vogel, C.¹ Cobleigh, M.² Tripathy, D.³ Harris, L.⁴ Fehrenbacher, L.⁵ Slamon, D.⁶ Ash, M.⁷ Novotny, W.⁸ Stewart, S.⁹ Shak, S.¹⁰

27
- 0032851960
- An overview of monoclonal antibody therapy of cancer
- (1999) Semin Oncol , vol.26 , pp. 41-50
- Weiner, L.M.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.